Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy
Cancer Immunology, Immunotherapy · 27.01.2026 · 75 (2)
DOI: 10.1007/s00262-025-04278-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 27.01.2026. Verfasst von Zhiwei Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou, Zhejiang, 311215, PR China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 226 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, National Natural Science Foundation of China, 2023 Hangzhou West Lake Pearl Project Leading Innovative Youth Team Project.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy has shown transformative success in hematologic malignancies, yet its application in solid tumors remains limited by a combination of intrinsic and extrinsic barriers. Intrinsically, CAR-T cells face challenges such as CAR instability, T cell exhaustion, insufficient tumor infiltration, and poor persistence. Extrinsically, the tumor microenvironment (TME) acts as a formidable obstacle, with physical barriers, metabolic constraints, and immunosuppressive signals that dampen CAR-T cell function. Recent advancements in CAR transduction, genetic reprogramming, and combination therapies have revealed novel strategies to overcome these hurdles. This review explores cutting-edge innovations aimed at unleashing the full potential of CAR-T therapy in solid tumors, focusing on strategies that enhance CAR-T cell function and persistence while addressing the immunosuppressive TME. By examining both intrinsic and extrinsic factors, we provide a comprehensive framework for future research and clinical application to improve CAR-T therapy for solid tumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou, Zhejiang, 311215, PR China.
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine & Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, 310003, People's Republic of…
- Department of Neurosurgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
- Department of General Surgery, Center for Metabolism Research, The Fourth Affiliated Hospital of Zhejiang University School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejian…
- ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou, Zhejiang, 311215, PR China. L210136@zju.edu.cn.
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- National Natural Science Foundation of China
- 2023 Hangzhou West Lake Pearl Project Leading Innovative Youth Team Project
Zitieren
APA
Zhang, Z., Cui, D., Wang, H., Wu, L., & Liu, X. (2026). Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. Cancer Immunology, Immunotherapy, 75(2). https://doi.org/10.1007/s00262-025-04278-8
Vancouver
Zhang Z, Cui D, Wang H, Wu L, Liu X. Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. Cancer Immunology, Immunotherapy. 2026;75(2). doi:10.1007/s00262-025-04278-8
BibTeX
@article{Zhang2026,
author = {Zhang, Zhiwei and Cui, Dawei and Wang, Hao and Wu, Liming and Liu, Xia},
title = {Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
volume = {75},
number = {2},
doi = {10.1007/s00262-025-04278-8}
}
EUVIMED